uploads/2018/06/health-2662312_1280.jpg

Analyst Recommendations for Boston Scientific and Peers in June

By

Updated

Analyst recommendations

Of the 24 analysts covering Boston Scientific in June, 19 of them have given the stock a “buy” or higher rating. Five of them have given it a “hold.” The mean rating for the stock is 1.67 with a target price of $32.76.

Peer ratings

In June, 16 of the 20 analysts covering Abbott Laboratories (ABT) gave the stock a “buy” or higher rating. Four of them gave it a “hold.” The mean rating for the stock is 1.85 with a target price of $68.56.

Of the 19 analysts covering Becton Dickinson (BDX) in June, 13 of them have given the stock a “buy” or higher rating, and six have given it a “hold.” The mean rating for the stock is 1.89 with a target price of $252.65.

Of the 17 analysts covering Baxter International (BAX) in June, ten of them have given the stock a “buy” or higher rating, and six have given it a “hold.” One analyst has given the stock a “sell” rating. The mean rating for the stock is 2.29 with a target price of $78.33.

Company overview

Boston Scientific (BSX) is a global company engaged in developing and bringing to market innovative medical devices that are used in a broad range of medical specialties. The company’s products and technologies are used for diagnosing cardiovascular, digestive, respiratory, urological, pelvic health, and neurological conditions.

In the next part of this series, we’ll take a look at Boston Scientific’s recent acquisitions.

More From Market Realist